KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationCost Of RevenueCustomer Additions AnnualCustomers Count AnnualDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Income Taxes By RegionLong Lived AssetsNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNo. Of Genes ShippedNo. Of Genes Shipped AnnualNo. Of Orders TotalNo. Of Orders Total AnnualNo. Of ShipmentsOpex As A % Of Total Revenue %OPEX SegregationOrder BreakdownProperty And Equipment, Net BreakdownRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By IndustryRevenue By Industry %Revenue By Industry AnnualRevenue By Industry Annual %Revenue By ProductRevenue By Product %Revenue By Product AnnualRevenue By Product Annual %Revenue Mix From Repeat Customers %Shipped ProductsValue Of Orders
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Twist Bioscience (TWST) Cost Of Revenue (2018 - 2025)

Twist Bioscience has reported Cost of Revenue over the past 10 years, most recently at $53.6 million for Q1 2026.

  • Quarterly Cost of Revenue rose 14.6% to $53.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $196.3 million through Mar 2026, up 5.91% year-over-year, with the annual reading at $185.6 million for FY2025, 3.31% up from the prior year.
  • Cost of Revenue was $53.6 million for Q1 2026 at Twist Bioscience, up from $49.7 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $53.6 million in Q1 2026 and troughed at $29.4 million in Q4 2022.
  • The 5-year median for Cost of Revenue is $44.4 million (2024), against an average of $42.1 million.
  • Year-over-year, Cost of Revenue surged 56.16% in 2022 and then fell 3.1% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $29.4 million in 2022, then surged by 44.47% to $42.5 million in 2023, then grew by 7.85% to $45.9 million in 2024, then rose by 8.4% to $49.7 million in 2025, then increased by 7.78% to $53.6 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Cost of Revenue are $53.6 million (Q1 2026), $49.7 million (Q4 2025), and $48.2 million (Q3 2025).